The project was led by GenIbet (www.genibet.com) in partnership with iBET and the Novartis Vaccines Institute for Global Health. Read here the interview with GenIbet's CEO, Raquel Fortunato.
Bernardo Abecasis, PhD student at the Animal Cell Technology Unit (iBET/ITQB NOVA), was awarded with the Best Poster Snapshot Presentation at the Scale-Up and Manufacturing of Cell-based Therapies V08.02.2017
The conference took place at San Diego, California, USA (15-19 January).
Improved tumor cell models are paramount to overcome current shortcomings of pre-clinical research and drug discovery02.01.2017
A perspective view from the team of the Advanced Cell Models Laboratory | Animal Cell Technology Unit of iBET and partners from AbbVie.
Yesterday iBET received the visit of Frank Stangenberg-Haverkamp, Chairman of the Executive Board of Merck KG04.11.2016
During his visit to Portugal, Frank Stangenberg-Haverkamp took the opportunity to visit two research institutes that showcase the high scientific expertise that Portugal has offer: iBET and Fundação Champalimaud.
The first ESACT Frontiers Retreat took place October 20th – 22nd 2016 in Lyon, France
Daniel Simão, researcher from the Animal Cell Technology Unit (iBET/ITQB NOVA), was awarded with the Best Young Scientist Oral Presentation at the 19th Congress of the European Society of Toxicology in vitro (ESTIV)26.10.2016
The meeting took place in Juan-les-Pins, France (17-20 October 2016)